Finance
Eli Lilly Oral Obesity Pill Retains Competitive Edge Despite Investor Concerns
CNBC reports that Eli Lilly's daily obesity pill could still compete effectively in the weight loss drug market. The assessment comes after the company released late-stage trial data in early August 2025 that disappointed Wall Street expectations. Eli Lilly's oral drug, orforglipron, caused 12.4% weight